-
Key Brands
-
Revenue
-
Performance
| Arixtra | Durateston | Fraxiparine | Sandostatin | Ultiva | Xylocaine |
|---|---|---|---|---|---|
| Anticoagulant | Testosterone replacement therapy |
Low molecular weight heparin/vascular |
Hormone replacement – bone and tumour regimens |
Opioid analgesic for anaesthesia |
Regional anaesthetic |
2025
23%
of Group revenue
28%
of Group gross profit
Asia
34
Americas
22
Africa Middle East
18
Europe CIS
17
Australasia
9
| Revenue | 2025 R'million |
2024 R'million |
% Change Reported |
CER |
|---|---|---|---|---|
| Asia | 3 324 | 3 112 | 7 | 10 |
| Americas | 2 177 | 2 395 | (9) | 4 |
| Africa Middle East | 1 771 | 1 218 | 45 | 48 |
| Europe CIS | 1 690 | 1 903 | (11) | (10) |
| Australasia | 923 | 856 | 8 | 13 |
| Total | 9 885 | 9 484 | 4 | 10 |
| Gross profit (%) | 53.2 | 58.2 |
The Injectables portfolio returned to growth in FY2025, rising 4% (10% CER) to R9 885 million compared to the
previous year. Africa Middle East revenue growth of 45% (48% CER) was boosted by the successful launch and roll-out
of Mounjaro® in South Africa. The product swap transaction with Sandoz impacted Asia positively and Europe
negatively. Solid growth in Americas (4% CER) and Australasia (13% CER) benefitting from improved product supply.
The gross profit margin of 53,2% (compared to 58,2% in FY2024) was affected by the VBP in China and the related one-off inventory write-offs.
The gross profit margin of 53,2% (compared to 58,2% in FY2024) was affected by the VBP in China and the related one-off inventory write-offs.
